Davita DVA

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. Fitch: Mixed Fourth Quarter Earnings for Morgan Stanley


      Tue, 20 Jan 2015

      according to Fitch Ratings. There were a number of items in the quarter which impacted results including a tax benefit for $1.4 billion and a DVA charge of $223 million which positively impact results and $1.1 billion of accelerated co

    2. Continued Net Interest Income Build More Meaningful for Morgan Stanley Than Trading Dip


      Tue, 20 Jan 2015

      compared to the recent quarterly run rate, and more than $0.50 to earnings per share. On an adjusted basis, excluding DVA and FVA, fixed-income and commodities trading revenue decreased to $599 million in the quarter from $997 million in the

    3. Fitch: Citi's 4Q'14 Results Cap Off a Disappointing Year


      Fri, 16 Jan 2015

      ongoing drag of legal-related charges on the company, and the difficult operating environment. Excluding the impact of CVA/ DVA during all periods, Citi's adjusted return on assets (ROA) was just 7 basis points (bps) in 4Q'14, and 40bps for the

    4. Fitch: JPMorgan Reports Record Net Income for 2014; 4Q Results Hurt by Credit and Legal Expenses


      Wed, 14 Jan 2015

      although Fitch Ratings believes 4Q'14 earnings were down 5.2% from the prior year (adjusting for legal expenses, FVA/ DVA implementation and adjustments, and non-recurring gains recorded in 4Q13). On a core basis, earnings were down due largely

    5. From Barron’s, January 5, 2015 (Part 1)


      Sat, 3 Jan 2015

      for a rebound play. Strong large-cap performers with significant insider activity include KMI, REGN, RSG, VRX, CHTR, DVA , TWX . For the week , DJIA -1.22% , SP500 -1.46% , Nasdaq Comp -1.67% , Russell 2000 -1.35% . DJ Transports -1

    6. DaVita Highlights Unsurprising 2015 Outlook in Light of Ongoing Payment Pressure


      Fri, 7 Nov 2014

      DaVita HealthCare Partners delivered third-quarter ..... outlook, since we have previously highlighted DaVita 's ongoing reimbursement challenges from ..... our view. Nonetheless, we still think DaVita continues to navigate this challenging environment

    7. Fresenius Continues to Slowly Overcome Challenges in Third-Quarter Results


      Tue, 4 Nov 2014

      think Fresenius has navigated recent reimbursement pressure in the dialysis market less successfully than its closes peer, DaVita . Fresenius' 6.6% organic growth this quarter showed modest improvement over recent results. Organic revenue growth of

    8. A Shift in Health-Care M&A Activity


      Sat, 23 Aug 2014

      Speaking of diabetes, how do you view DaVita HealthCare Partners DVA as a potential Berkshire Hathaway ..... certain amount of attractiveness for DaVita in that diabetes is a big contributor to dialysis and DaVita is one of the largest dialysis providers

    9. Kidney Care Remains DaVita ’s Bright Spot in a Tough Environment


      Fri, 1 Aug 2014

      Despite weakness in both of DaVita HealthCare Partners’ business segments ..... reduction in administrative costs, DaVita upheld healthy segment operating margin ..... treatment growth to remain strong for DaVita . We also expect profitability to improve

    10. Fresenius Meets Expectations and Cautiously Enters Coordinated-Care Market


      Thu, 31 Jul 2014

      Illinois and Texas. We're usually skeptical of deals outside of management's expertise in dialysis, a criticism we share with DaVita 's large merger with Healthcare Partners. While we think Fresenius' global dominance in the dialysis market is enough to

    « Prev12345Next »
    Content Partners